End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.3 SEK | +0.46% | +2.85% | +29.64% |
May. 15 | Transcript : EQL Pharma AB, Q4 2024 Earnings Call, May 15, 2024 | |
May. 14 | Eql Pharma AB Provides Sales Guidance for the Year 2024/25 | CI |
Sales 2024 | 264M 24.71M | Sales 2025 * | 367M 34.33M | Capitalization | 1.26B 118M |
---|---|---|---|---|---|
Net income 2024 | 22M 2.06M | Net income 2025 * | 54M 5.05M | EV / Sales 2024 | 4.65 x |
Net Debt 2024 * | 104M 9.73M | Net Debt 2025 * | 85M 7.95M | EV / Sales 2025 * | 3.66 x |
P/E ratio 2024 |
55.7
x | P/E ratio 2025 * |
23.3
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Latest transcript on EQL Pharma AB
1 day | +0.46% | ||
1 week | +2.85% | ||
Current month | -0.23% | ||
1 month | +1.41% | ||
3 months | +20.28% | ||
6 months | +45.79% | ||
Current year | +29.64% |
Managers | Title | Age | Since |
---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 18-01-31 |
Founder | 59 | 05-12-31 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 21-12-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 59 | 05-12-31 | |
Director/Board Member | 64 | 14-12-31 | |
Director/Board Member | 51 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 43.3 | +0.46% | 10,627 |
24-05-16 | 43.1 | -0.69% | 12,353 |
24-05-15 | 43.4 | +8.50% | 56,175 |
24-05-14 | 40 | +0.76% | 13,700 |
24-05-13 | 39.7 | -5.70% | 48,805 |
End-of-day quote NORDIC GROWTH MARKET, May 16, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.64% | 118M | |
-31.39% | 15.68B | |
-20.59% | 12.39B | |
-21.23% | 6.74B | |
-6.15% | 6.29B | |
+10.76% | 6.26B | |
+70.00% | 4.95B | |
-2.48% | 4.66B | |
-5.58% | 4.03B | |
-9.24% | 3.62B |
- Stock Market
- Equities
- EQL Stock